Biocon Biologics is a global leader in biologics, which is delivering affordable access to innovative and inclusive healthcare solutions. We are leveraging our cutting-edge science, innovative tech platforms, advanced research & development capabilities and global scale manufacturing capacities to lower treatment costs while improving healthcare outcomes worldwide. We have built one of the broadest and deepest pipelines in the biosimilars industry straddling monoclonal antibodies for cancer and autoimmune diseases, insulin and insulin analogs for diabetes and conjugated recombinant proteins. We are one of the leading insulins producers globally with a portfolio comprising basal, mixed and rapid acting insulins. We have taken six molecules from ‘lab to market’ to make a difference to patients in developed markets and key emerging markets.
We have several firsts to our credit, including the most recent U.S. Food and Drug Administration approval of the world’s first interchangeable biosimilar, received for our Insulin Glargine. Having proven our capabilities in biosimilars, we are expanding our therapeutic focus to include infectious diseases with the objective of addressing inequitable access both in emerging and developed markets for life-saving vaccines and biologics. With a team of ~ 4,800 people, Biocon Biologics is committed to transforming healthcare and transforming lives by enabling affordable access to millions of patients’ worldwide.
